Eye Treatment – Lutra Vision http://lutravision.com/ Wed, 21 Sep 2022 09:31:49 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://lutravision.com/wp-content/uploads/2021/11/lutra-vision-icon-120x120.jpg Eye Treatment – Lutra Vision http://lutravision.com/ 32 32 Uveitis Treatment Market Growth, Size, Analysis, Outlook https://lutravision.com/uveitis-treatment-market-growth-size-analysis-outlook/ Wed, 21 Sep 2022 09:31:49 +0000 https://lutravision.com/uveitis-treatment-market-growth-size-analysis-outlook/ Uveitis Treatment Market The Global Uveitis Treatment Market is valued at USD 703.54 Million in 2022 and is projected to reach a value of USD 958.91 Million by 2030, growing at a CAGR of 5.32% over the forecast period 2022- 2030. Uveitis is considered a type of infection that causes inflammation of the eye. It […]]]>

Uveitis Treatment Market

The Global Uveitis Treatment Market is valued at USD 703.54 Million in 2022 and is projected to reach a value of USD 958.91 Million by 2030, growing at a CAGR of 5.32% over the forecast period 2022- 2030.

Uveitis is considered a type of infection that causes inflammation of the eye. It typically affects the middle layers of eye wall tissue called the uvea.

Some of the common symptoms related to this condition include pain, redness, swelling, blurred vision, sensitivity to light, as well as floating dark spots in the field of vision.

Most cases of uveitis can be treated with antivirals, antibiotics, and steroids along with anti-inflammatory eye drops. It can also take at least 2 to 5 weeks for this condition to clear up, while in severe cases, recovery can take months.

The growing ubiquity of the disease, rising healthcare expenditures globally, and increasing R&D activities in the field are driving the market growth over the forecast period.

Additionally, the growing focus of drug manufacturers on developing and launching effective drugs in the field has created lucrative opportunities for the market to flourish.

Main market trends
Each market has its growth determinants and challenges. One of the major factors fueling the growth of the market over the forecast period is the growing geriatric population.

Also, the elderly population is very susceptible to eye disorders, such as uveitis. This is fueled by the fact that aging people have weakened immune systems and therefore easily catch viral infections.

Thus, a wide range of treatment options are being prescribed for the elderly with this disease and have driven the growth of the market over the forecast period.

Additionally, there has been an increasing ubiquity of eye conditions around the world. This is attributed to the deterioration of the immune system of the masses due to unhealthy lifestyle habits.

Also, increasing pollution levels and increasing geriatric population lead to an increase in the number of people with ophthalmic disorders. These factors have boosted the growth of the market over the forecast period.

Get a free sample report: https://wemarketresearch.com/sample-request/uveitis-treatment-market/401/

Market segment analysis

Based on type of treatment
• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Cycloplegic agents
• Antibiotics
• Antiviral
• Antifungal
• Analgesics
The corticosteroids segment is poised to rack up notable gains over the stipulated period owing to the effectiveness of these drugs in reducing inflammation in patients with uveitis.

Based on disease type
• Anterior uveitis
• Posterior uveitis
• Intermediate uveitis
• Panuveitis
The anterior uveitis segment is expected to generate significant returns over the estimated duration due to its increasing ubiquity among young adults.

Cause-based
• Infectious
• Non-infectious
The infectious segment is expected to grow significantly by 2030 due to the severity of infectious uveitis.

Based on distribution channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
The online pharmacy segment is expected to account for a high volume share over the span of the analysis, credited to their advantageous features such as home delivery and discount offers.
North America is expected to expand at a considerable CAGR

The global uveitis treatment market is segmented into 4 major regions, namely North America, Europe, Asia-Pacific, Middle East and Africa. Among these, North America led the market growth over the forecast period. This is due to the increasing prevalence of autoimmune diseases, the increase in the geriatric population and the increase in healthcare expenditures around the world.

For more details, visit our report page: https://wemarketresearch.com/reports/uveitis-treatment-market/401/

Competitive landscape
Some of the major companies operating in the market are Allergan; Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co.; Ltd; AbbVie Inc.; Novartis SA; Eyegate Pharmaceuticals; Inc.; Regeneron Pharmaceuticals; Eyepoint Pharmaceuticals Inc.; and Alimera Sciences; Inc.

Frequently Asked Questions
• What is the growth rate of the global uveitis treatment market?
• What are the main determinants of market growth?
• What are the major regions that make up the geographic landscape of the market?
• What are the main companies operating in the market?

Contact us:
We study the market
Phone: +1(650)-666-4592
Email: sales@wemarketresearch.com
The Web: https://wemarketresearch.com/

About We Market Research:
WE MARKET RESEARCH is an established market analysis and research company with domain experience spanning different industries. We have worked on multi-county market research since our inception. Over time since our existence, we have won accolades for our deep-rooted market research and insightful analysis of various markets.
Our strategic market analysis and ability to understand the deep cultural, conceptual and social aspects of various entangled markets has helped us stand out in the industry. WE MARKET RESEARCH is a pioneer in supporting many companies; both regionally and internationally to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of designing market strategies that ensure guaranteed customer bases for our clients.

This press release was published on openPR.

]]>
Recon: FDA Approves Bluebird Bio’s Gene Therapy Treatment for Rare Neurological Disorders; E https://lutravision.com/recon-fda-approves-bluebird-bios-gene-therapy-treatment-for-rare-neurological-disorders-e/ Mon, 19 Sep 2022 17:55:40 +0000 https://lutravision.com/recon-fda-approves-bluebird-bios-gene-therapy-treatment-for-rare-neurological-disorders-e/ Acknowledgement | September 19, 2022 | By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your daily update on regulatory news and intelligence. In brief: United States US FDA approves bluebird bio’s gene therapy for rare neurological disorder (Reuters) (Biospace) Heron gets FDA green light for Aponvie, an intravenous alternative to pills for post-surgery […]]]>
Acknowledgement

| September 19, 2022 | By Joanne S. Eglovitch

Welcome to Regulatory Reconnaissance, your daily update on regulatory news and intelligence.

In brief: United States

  • US FDA approves bluebird bio’s gene therapy for rare neurological disorder (Reuters) (Biospace)
  • Heron gets FDA green light for Aponvie, an intravenous alternative to pills for post-surgery nausea (Fierce)
  • FDA Action Alert: Regeneron, Spectrum and more (Biospace)
  • Amylyx’s commitment against ALS. FDA’s Obscure Withdrawal Authority: Which Holds the Most Power? (pink sheet)
  • Biden directive on screening foreign investment in US biotech does not target China, administrative officials say (Endpoints)
  • RWE in numbers: analysis of FDA use over the years (pink sheet)
  • New report examines top blockbusters and their use of patents to block competition (Endpoints) (FDAnews)
  • Soaring prices fuel campaign for new drug cost crackdown (Bloomberg)
  • FDA pharma fees fuel influence concerns (NYT)
  • Pfizer accused of running racially discriminatory scholarship program (STAT)
  • ‘I am deeply worried’: Francis Collins on trust in science, Covid communications failure and his current obsession (STAT)

Focus: International

  • EMA approves first drug to prevent RSV infection in babies (pink sheet) (endpoints)
  • After scoring success in US study, Pfizer wins EU infant victory for 20-valent pneumococcal vaccine (Fierce)
  • EU regulator backs wider use of AstraZeneca COVID therapy (Reuters)
  • Moderna helps WHO mRNA hub, Pfizer snubs Request (Bloomberg)
  • Chinese scientists develop mask that detects Covid and flu exposure (Bloomberg)
  • Lancet commission slams WHO and governments over their Covid response (Endpoints)
  • Pharmaceutical companies are closely watching NICE’s new HTA approach in the UK (pink sheet)
  • Ghana declares an end to the Marburg virus disease outbreak (Reuters)

Pharmaceuticals and biotechnology

  • AmerisourceBergen throws nearly $1.3 billion in cash for German life sciences company (Endpoints)
  • Bristol Myers Squibb and Abbvie to cut 360 jobs across California (Biospace)
  • Moderna CEO looks to Japan to build new vaccine manufacturing site (Endpoints)
  • Theravance declares independence from GSK and develops $250 million plan to buy back its own shares (Endpoints)
  • Bryn advances anaphylaxis nasal spray after completing pivotal trial (Fierce)
  • Genfit Accelerates Liver Failure Strategy with $41M Biotech Buyout and Phase 2-Ready Candidate (Fierce)
  • Fortress Falls: Virious misses fibromyalgia study, but claims drug could work in omicron era (Fierce)
  • The alleged clinical benefits of TAVR brain protection remain unproven (Medpage Today)
  • Intellia says CRISPR treatment safely fixes DNA in six patients with rare disease (STAT) (Fierce)

medical technology

  • FDA Updates Advice on Medtronic Endotracheal Tubes After Class I Recall, Patient Death Reports (MedTech Dive)

  • FDA places Class I label on Baxter’s recall of Clearlink (Fierce) Chemotherapy Administration Sets (MedTech Dive)
  • Racial bias in pulse oximeters will be the subject of an FDA panel (MedTech Dive)
  • Medical Devices Excluded from EU Cyber ​​Resilience Bills (MedTech Insight)
  • Industry needs strong regulations now to counter Europe’s tough challenges (MedTech Insight)
  • Boston Scientific’s TAVR safety net device misses study endpoint in stroke reduction (Fierce)
  • Johnson & Johnson pours 100 million euros into a contact loan factory in Ireland (Fierce) (Endpoints)
  • Private equity sees billions in eye care as companies target high-profit procedures (Fierce)

Government, regulation and legal

  • Teva plans to start paying for US opioid settlement in 2023 (Reuters) (Endpoints)
  • Judge Axes 2 patents for anti-epileptic drugs, confirms 3 others (Law360)
  • A month after GSK’s victory in Zantac cancer case, plaintiffs file dozens more lawsuits (Endpoints)
  • J&J Talc Bankruptcy ‘Bad faith’ claims go ahead of Third Circuit (Bloomberg)
  • Liquidia appeals lung drug ruling infringing UTC’s patent (Bloomberg)
  • Zealand Pharma sued for misuse of trade secrets (Medwatch)

Regulatory Recon is our daily intelligence briefing for regulatory affairs, bringing you top regulatory, biopharma and medtech news from around the world.
Inclusion of a story in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

© 2022 Society of Regulatory Affairs Professionals.


]]>
Signs, causes and treatment of eye strain headaches https://lutravision.com/signs-causes-and-treatment-of-eye-strain-headaches/ Sat, 17 Sep 2022 12:28:05 +0000 https://lutravision.com/signs-causes-and-treatment-of-eye-strain-headaches/ You should note that experiencing eye strain does not mean that your eyes are injured or damaged. Headaches and eye fatigue go away after you give your eyes a good rest Representative image. Shutterstock There are various things that can lead to a headache. We all know how uncomfortable and unbearable pain can be. The […]]]>

You should note that experiencing eye strain does not mean that your eyes are injured or damaged. Headaches and eye fatigue go away after you give your eyes a good rest

Representative image. Shutterstock

There are various things that can lead to a headache. We all know how uncomfortable and unbearable pain can be. The pain you feel may be extreme or mild, depending on the underlying reason.

One of the causes of headaches is eye strain. This can happen after engaging in activities like concentrating intently on a computer screen for too long or after a long car ride. It can make you feel blurry, exhaustion and irritation in your eyes.

You should keep in mind that experiencing eye strain does not mean that your eyes are injured or damaged. Headaches and fatigue go away once you rest your eyes.

Signs of an eye strain headache:

You feel pain behind your eyes
You might feel pain behind or around your eyes, and the area where you feel pain might be sore or tired.

No digestive issues
An eye strain headache is usually not associated with vomiting or nausea. So, unlike other types of headaches, you won’t experience nausea or any other digestive-related issues.

It develops after prolonged activity
You develop an eye strain headache after overusing your eyes during activities such as staring at your phone screen for hours or reading a book continuously.

Causes of a headache due to eyestrain:

Some of the causes of a headache due to eyestrain are:

1. Uncorrected vision.
Uncorrected vision can also cause eyestrain headaches. Glasses or contact lenses can solve the problem. Your eyes work harder to form a clear image when your vision is uncorrected. This can lead to an eye strain headache.

2. Exposure to bright or dim light.
You may experience eyestrain headaches after being exposed to bright light, such as sunlight, or dim light for too long. When your eyes are working hard to focus, you may experience headaches.

3. Prolonged use of contact lenses.
Prolonged use of contact lenses can cause eye irritation and fatigue.

Treatment of headaches related to eyestrain:

You can moisten your eyes by applying eye drops as dryness can make eyestrain worse. Further, you simply need to close your eyes and rest them for several minutes. Putting an ice pack or a cold towel on your forehead can also provide relief.

Read all Recent news, New trends, Cricket News, bollywood news,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

]]>
Concerns over treatment of ‘loving and bubbly’ Heywood woman before her death https://lutravision.com/concerns-over-treatment-of-loving-and-bubbly-heywood-woman-before-her-death/ Fri, 16 Sep 2022 04:00:00 +0000 https://lutravision.com/concerns-over-treatment-of-loving-and-bubbly-heywood-woman-before-her-death/ The family of a ‘loving and bubbly’ woman have raised concerns about her treatment by paramedics before her death. Kimberley Ann Irvine, 38, arrived at Fairfield General Hospital in Bury by ambulance on Thursday March 10 where she was confirmed dead. Emergency services were called to Ms Irvine’s home on Mount Street, Heywood, after experiencing […]]]>

The family of a ‘loving and bubbly’ woman have raised concerns about her treatment by paramedics before her death.

Kimberley Ann Irvine, 38, arrived at Fairfield General Hospital in Bury by ambulance on Thursday March 10 where she was confirmed dead.

Emergency services were called to Ms Irvine’s home on Mount Street, Heywood, after experiencing difficulty breathing earlier in the morning.

The inquest, held at Rochdale Coroner’s Court, heard that Bury-born Ms Irvine suffered from various health conditions before her death and is awaiting the results of an EKG.

The court heard that due to Ms Irvine’s size, paramedics had difficulty carrying her up the stairs in her home using a chair and asked her to walk down the stairs on her buttocks.

Once at the foot of the stairs, Ms Irvine was placed in a bariatric chair and wheeled outside where she collapsed and fell to the ground.

In a statement, Ms Irvine’s father, Dennis Irvine, told the court he believed the way paramedics treated his daughter contributed to her death.

He said: ‘I heard a squeal then a scream, Kimberly fell onto the road and looked petrified, a paramedic grabbed her arm but her head hit the road.

“Her eyes were wide open but then went absolutely black when she fell.”

“His whole body hit the ground.”

Duncan Mayoh, an advanced paramedic with the North West Ambulance Service (NWAS), said when the ambulance crew arrived at Ms Irvine’s home she had blue hands and was “very, very sick”.

The crew put her on oxygen, but Ms Irvine’s heart rate and breathing increased as they tried to help her out of the house.

Mr Mayoh said asking Ms Irvine to walk down the stairs on her butt was “not common practice” but was “the only option” in the circumstances.

He added that Ms Irvine’s fall to the ground was “controlled” as it was necessary for her to be lying down while paramedics resuscitated her.

Mr Mayoh added: “We had to put the patient on the floor, the only way to do CPR is on the floor.”

He admitted Ms Irvine could have hit her head after falling in the road.

Dr Emil Salmo, consultant pathologist at the Royal Oldham Hospital, told the court he found evidence of ‘minor injuries’ during Ms Irvine’s post-mortem examination, including bruising to the scalp, but said it would be difficult to confirm when it happened.

During an internal examination, Dr Salmo discovered that Ms Irvine had an enlarged heart and there were signs of blood clots in her lungs.

He told the court he believed she died of pulmonary thromboembolism, a blood clot in the lungs.

Greater Manchester North Deputy Coroner Matthew Cox concluded Ms Irvine died of natural causes and gave a medical cause of death of a bilateral pulmonary embolism which caused cardiac arrest.

Ms Irvine was born at Fairfield General Hospital in Bury, but grew up and educated in Heywood.

She had been diagnosed with dyslexia, but overcame it to earn a master’s degree.

Her mother, Irene Newall, described her daughter as a “loving, bubbly woman who adored her family and would help her parents with anything”.

]]>
Wearable devices can predict depression treatment outcomes: Research | Health https://lutravision.com/wearable-devices-can-predict-depression-treatment-outcomes-research-health/ Wed, 14 Sep 2022 13:02:08 +0000 https://lutravision.com/wearable-devices-can-predict-depression-treatment-outcomes-research-health/ Managing his mental health has been a higher priority in recent years, with an increased emphasis on self-care. Every year, more than 300 million people around the world suffer from depression. Recognizing this, there’s a lot of interest in using popular wearables to monitor a person’s mental health by tracking markers like activity level, sleep, […]]]>

Managing his mental health has been a higher priority in recent years, with an increased emphasis on self-care. Every year, more than 300 million people around the world suffer from depression. Recognizing this, there’s a lot of interest in using popular wearables to monitor a person’s mental health by tracking markers like activity level, sleep, and heart rate. (Also read: Exercising for 30 minutes can reduce symptoms of depression and boost effects of therapy: study )


A team of researchers from Washington University in St. Louis and the University of Illinois in Chicago used data from wearable devices to predict depression treatment outcomes in people who took part in a trial randomized clinic. They developed a new machine learning model that analyzes data from two groups of patients – those randomly selected to receive treatment and those who did not receive treatment – instead of developing a separate model for each group. This unified multitasking model is a step toward personalized medicine, in which doctors design a treatment plan specific to each patient’s needs and predict outcomes based on an individual’s data.

The research results have been published in the ACM Proceedings on Interactive, Model, Wearable and Pervasive Technologies and will be presented at the UbiComp 2022 conference in September. Chenyang Lu, a Fullgraf professor at the McKelvey School of Engineering, led a team that included Ruixuan Dai, who worked in Lu’s lab as a doctoral student and is now a software engineer at Google; Thomas Kannampallil, associate professor of anesthesiology and associate director of research information at the School of Medicine and associate professor of computer science and engineering at McKelvey Engineering; and Jun Ma, MD, PhD, professor of medicine at the University of Illinois at Chicago (UIC); and colleagues to develop the model using data from a randomized clinical trial conducted by UIC with approximately 100 adults with depression and obesity.


“Integrated behavioral therapy can be expensive and time-consuming,” Lu said. “If we can make personalized predictions for individuals about how likely a patient will respond to a particular treatment, then patients can’t continue treatment that if the model predicts that their condition will likely improve with treatment but less likely without treatment, personalized predictions of treatment response will facilitate more targeted and cost-effective therapy.”

In the trial, patients were given Fitbit wristbands and psychological tests. About two-thirds of the patients received behavioral therapy, and the remaining patients did not. Patients in the two groups were statistically similar at baseline, giving the researchers a level playing field from which to discern whether the treatment would lead to better outcomes based on individual data.


Clinical trials of behavioral therapies often involved relatively small cohorts due to the cost and duration of these interventions. The small number of patients created a challenge for a machine learning model, which generally works better with more data. However, by combining data from both groups, the model could learn from a larger data set, which captured the differences between those who had undergone treatment and those who had not. They found that their multitasking model predicted depression outcomes better than a model examining each of the groups separately.

“We pioneered a multitasking framework, which combines the intervention group and the control group in a randomized controlled trial to jointly train a unified model to predict an individual’s personalized outcomes with and without treatment,” said Dai, who earned a doctorate in computer science. science in 2022. “The model integrated clinical features and wearable data into a multi-layered architecture. This approach avoids dividing study cohorts into small groups for machine learning models and enables dynamic knowledge transfer between groups to optimize prediction performance for both with and without intervention.”


“The implications of this data-driven approach extend beyond randomized clinical trials to implementation in the delivery of clinical care, where the ability to make personalized predictions of patient outcomes based on treatment received, and to do so early and throughout treatment, could significantly inform shared decision-making by the patient and treating physician to tailor the treatment plan for that patient,” Ma said.

The machine learning approach provides a promising tool for building personalized predictive models based on data collected from randomized controlled trials. Going forward, the team plans to leverage the machine learning approach in a new randomized controlled trial of telehealth behavioral interventions using Fitbit wristbands and weight scales in patients in an intervention study. of weight loss.


Follow more stories on Twitter & Facebook

This story was published from a news feed with no text edits. Only the title has been changed.

]]>
Elvis Presley gets the Hollywood treatment, again, with Sofia Coppola’s new A24 movie Priscilla https://lutravision.com/elvis-presley-gets-the-hollywood-treatment-again-with-sofia-coppolas-new-a24-movie-priscilla/ Mon, 12 Sep 2022 19:41:00 +0000 https://lutravision.com/elvis-presley-gets-the-hollywood-treatment-again-with-sofia-coppolas-new-a24-movie-priscilla/ Obviously, fans of the musical icon and Sofia Coppola herself will have an eye on the cast of “Priscilla,” especially after Austin Butler and Olivia DeJonge brought both roles to such vivid life in the recent “Elvis” biopic. Along these lines, Deadline also reports that Cailee Spaeny has always been Coppola’s first choice for Priscilla […]]]>

Obviously, fans of the musical icon and Sofia Coppola herself will have an eye on the cast of “Priscilla,” especially after Austin Butler and Olivia DeJonge brought both roles to such vivid life in the recent “Elvis” biopic. Along these lines, Deadline also reports that Cailee Spaeny has always been Coppola’s first choice for Priscilla and has been officially brought in. Spaeny is a somewhat familiar face who has been seen in recent films such as ‘Pacific Rim: Uprising’, ‘Bad Times at the El Royale’, ‘On the Basis of Sex’ and most recently on the Showtime series ‘The First lady”. As for Elvis, the filmmaker courted several up-and-coming actors before finally stumbling upon Jacob Elordi, best known for his roles in Netflix’s ‘The Kissing Booth’ trilogy and HBO’s ‘Euphoria’.

A24 will distribute the film in North America, while Stage 6 Films/Sony Pictures International Releasing will handle worldwide distribution (excluding Italy, where Vision Distribution will take over before becoming a Sky exclusive). Fans of Coppola’s work will be delighted to hear that she’s reassembling the backstage crew again, joined by her cinematographer Philippe Le Sourd (“On the Rocks,” “The Beguiled”), editor Sarah Flack, production designer Tamara Deverell and costume designer Stacey Battat. Of course, this will mark the filmmaker’s last partnership with A24 after previous tours on “The Bling Ring” and “On the Rocks.”

Stay tuned to /Film for more details on “Priscilla” as they arrive.

]]>
Dermora eye masks give your skin a luxury treatment https://lutravision.com/dermora-eye-masks-give-your-skin-a-luxury-treatment/ Sun, 11 Sep 2022 05:08:23 +0000 https://lutravision.com/dermora-eye-masks-give-your-skin-a-luxury-treatment/ Us Weekly has affiliate partnerships, so we may receive compensation for certain links to products and services. Who hasn’t woken up with puffy eyes – either after a long night out or a stressful night of tossing and turning? We’ve all been there, and eye masks could seriously come to the rescue. These trusty treats […]]]>

Us Weekly has affiliate partnerships, so we may receive compensation for certain links to products and services.

Who hasn’t woken up with puffy eyes – either after a long night out or a stressful night of tossing and turning? We’ve all been there, and eye masks could seriously come to the rescue. These trusty treats have become increasingly popular – and for good reason.

Here’s the thing: the skin around the eyes is particularly sensitive, so it requires special care – and that’s why targeted treatments have grown in popularity. The eyes are also the first place we notice fatigue, and while there are tons of eye masks to choose from, we especially love the gold variety. They may seem expensive, but this set of DERMORA makes this treatment much more economical!

See it!

Get the DERMORA 24k gold eye mask for prices starting at $16 at Amazon! Please note that prices are accurate at the date of publication, August 12, 2022, but are subject to change.

These masks help fight puffiness by tightening the skin and making it appear less prominent, which can diminish the appearance of dark circles in the process. They can also help fight aging if you opt for a mask that fights fine lines and wrinkles. These masks only take about 15 minutes to work their magic, and once that’s done, you might just be able to see a completely fresh complexion!

See it!

Get the DERMORA 24k gold eye mask for prices starting at $16 at Amazon! Please note that prices are accurate at the date of publication, August 12, 2022, but are subject to change.

What we love most about these buyer-favorite masks is their affordability. Some versions of this style can be a real waste of your time, but you can score this set for as little as $16 for a 20-pack. Of course, if you decide to stock up, you’ll get an even better deal. ! These eye masks would compare to high-end brands, so if you’ve ever been interested in trying the trend, we can’t think of a better option than this set. It’s 24K magic!

See: Get the DERMORA 24k gold eye mask for prices starting at $16 at Amazon! Please note that prices are accurate at the date of publication, August 12, 2022, but are subject to change.

Not what you’re looking for? Check out more styles from DERMORA and shop all the beauty and personal care available on Amazon! Don’t forget to check out all of Amazon’s daily deals!

Still haven’t found what you’re looking for? Check out these articles on related products below:

Discover more of our choices and offers here!

This article is brought to you by the Shop With Us team at Us Weekly. The Shop With Us team aims to highlight products and services that our readers might find interesting and useful, such as wedding guest outfits, handbags, plus size swimwear, women’s sneakers , bridal wear and the perfect gift ideas for everyone in your life. The selection of products and services, however, is in no way intended to constitute an endorsement of Us Weekly or any celebrity mentioned in the post.

The Shop With Us team can receive products from manufacturers for free to test. Additionally, Us Weekly receives compensation from the manufacturer of the products we write about when you click on a link and then purchase the product featured in an article. This does not determine our decision as to whether a product or service is featured or recommended or not. Shop With Us operates independently of the advertising sales team. We appreciate your feedback at ShopWithUs@usmagazine.com. Good shopping!

]]>
Global Macular Degeneration Treatment Market Report 2022: Rising Burden of Retinal Disorders to Support Industry Growth – ResearchAndMarkets.com https://lutravision.com/global-macular-degeneration-treatment-market-report-2022-rising-burden-of-retinal-disorders-to-support-industry-growth-researchandmarkets-com/ Fri, 09 Sep 2022 12:32:00 +0000 https://lutravision.com/global-macular-degeneration-treatment-market-report-2022-rising-burden-of-retinal-disorders-to-support-industry-growth-researchandmarkets-com/ DUBLIN–(BUSINESS WIRE)–The Report “Global Market Report of Macular Degeneration Treatment Market 2022” has been added to from ResearchAndMarkets.com offer. The global macular degeneration treatment market is expected to grow from USD 7.55 billion in 2021 to USD 8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The market is expected to […]]]>

DUBLIN–(BUSINESS WIRE)–The Report “Global Market Report of Macular Degeneration Treatment Market 2022” has been added to from ResearchAndMarkets.com offer.

The global macular degeneration treatment market is expected to grow from USD 7.55 billion in 2021 to USD 8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The market is expected to reach $10.65 billion in 2026 with a CAGR of 7.15%.

In 2021, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest growing region during the forecast period. Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The growing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect vital tissues and affect how individuals process visual information, resulting in distorted or absent vision. According to a 2020 study in Tanzania on the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007).

The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery and drug therapy. The main retinal diseases were age-related hypertensive macular scarring (2.7%), retinopathy (4.5%) and degeneration (7.0%). According to the American Academy of Opthalmology, by 2050 an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest number among populations aged 70-79 (32%) , women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Hence, the growing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

The development of advanced therapies is a key trend that is gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has developed in recent years, particularly in the world of inherited retinal diseases.

For example, in 2019, Spark Therapeutics, a US-based gene therapy treatment company, developed Luxturna, a therapy designed to treat patients with mutations in a gene called RPE65, which encodes a retinal protein necessary for eye to respond to light.

In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition should enable Novartis to find treatments for patients with vision loss and exploit the potential of optogenetics as the basis for effective therapies. Arctos Medical is a Swiss developer of smart medical devices and gene therapy approaches for ophthalmological diseases for the treatment of blindness.

The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea South, the United Kingdom and the United States.

Scope

Covered markets:1) By disease stage: early-stage AMD; intermediate AMD; advanced AMD

2) By end user: ambulatory surgery centers; eye clinics; Hospitals

3) By route of administration: oral; injectables; Others

4) By types: wet macular degeneration, dry macular degeneration

Main topics covered:

1. Summary

2. Characteristics of the Macular Degeneration Treatment Market

3. Macular Degeneration Treatment Market Trends and Strategies

4. Impact of COVID-19 on the treatment of macular degeneration

5. Macular Degeneration Treatment Market Size and Growth

6. Macular Degeneration Treatment Market Segmentation

7. Regional and Country Analysis of Macular Degeneration Treatment Market

8. Asia-Pacific Macular Degeneration Treatment Market

9. Chinese Macular Degeneration Treatment Market

10. Macular Degeneration Treatment Market in India

11. Japan Macular Degeneration Treatment Market

12. Australia Macular Degeneration Treatment Market

13. Indonesia Macular Degeneration Treatment Market

14. South Korea Macular Degeneration Treatment Market

15. Western Europe Macular Degeneration Treatment Market

16. UK Macular Degeneration Treatment Market

17. Germany Macular Degeneration Treatment Market

18. France Macular Degeneration Treatment Market

19. Eastern Europe Macular Degeneration Treatment Market

20. Russia Macular Degeneration Treatment Market

21. North America Macular Degeneration Treatment Market

22. US Macular Degeneration Treatment Market

23. South America Macular Degeneration Treatment Market

24. Brazil Macular Degeneration Treatment Market

25. Middle East Macular Degeneration Treatment Market

26. Africa Macular Degeneration Treatment Market

27. Macular Degeneration Treatment Market Competitive Landscape and Company Profiles

28. Key mergers and acquisitions in the macular degeneration treatment market

29. Macular Degeneration Treatment Market Future Outlook and Potential Analysis

30. Appendix

Companies cited

  • Novartis AG

  • Bausch Health Companies Inc.

  • Regenxbio inc.

  • F Hoffmann-La Roche Ltd

  • Regeneron Pharmaceuticals Inc.

  • GlaxoSmithKline plc

  • Bayer AG

  • Neurotech Pharmaceutical Inc.

  • Ophthalmology company

  • Stem Cells Inc.

  • Pfizer Inc.

  • Santen Pharmaceuticals

  • Alimera Sciences Inc.

  • Aerie Pharmaceutical Inc.

  • Panopticon

  • Allergan Inc.

  • Valiant Pharmaceuticals

  • Rxi Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/6cqav8

]]>
FDA approves topical cream treatment for vitiligo https://lutravision.com/fda-approves-topical-cream-treatment-for-vitiligo/ Wed, 07 Sep 2022 20:03:45 +0000 https://lutravision.com/fda-approves-topical-cream-treatment-for-vitiligo/ It is estimated that more than one million Americans suffer from vitiligo. The autoimmune disease targets and destroys pigment cells in the body, causing white spots. The FDA recently approved the first drug treatment to restore pigment in the skin of vitiligo patients. Opzelura is a topical cream that belongs to a class of drugs […]]]>

It is estimated that more than one million Americans suffer from vitiligo. The autoimmune disease targets and destroys pigment cells in the body, causing white spots. The FDA recently approved the first drug treatment to restore pigment in the skin of vitiligo patients.

Opzelura is a topical cream that belongs to a class of drugs called JAK inhibitors. “The drug helps prevent the immune system from being overactive and destroying pigment cells in the body,” says Dr. David Rosmarin of Tufts Medical Center. He led the clinical trials. “One year of using the cream, about half of the patients using it recover 75% or more of their pigment on the face, and about half of the patients recover 50% or more of the pigment all over the body,” he says.

Berardo Rivas participated in the study. He saw results in three months and now has 95% pigmentation on his face. “I don’t think there are any other words to describe it other than happiness and joy that the treatment is actually working for me,” he said.

Rivas has lived with vitiligo for over 30 years. “I started seeing it right on my eyes, my hands, and I think it was here on the collarbone,” Rivas said. In adulthood, the condition worsened. He tried several therapies ranging from creams to UV light treatment and avoided the sun, but he says nothing really helped. “I was avoiding people, I was avoiding gatherings, I was avoiding going to the beach,” he said. Rivas hopes the cream will more than restore pigment for other patients like it did for him.

The treatment is approved for adults and children 12 years or older and requires a prescription. The researchers say that as a topical medication, it was well tolerated by patients and has a good safety profile.

]]>
A couple’s quest for treatment for their son with ASD faces repeated hurdles https://lutravision.com/a-couples-quest-for-treatment-for-their-son-with-asd-faces-repeated-hurdles/ Tue, 06 Sep 2022 02:10:02 +0000 https://lutravision.com/a-couples-quest-for-treatment-for-their-son-with-asd-faces-repeated-hurdles/ When Sebastian Rios was very young, he barely spoke. “Don’t worry,” his pediatrician told Amparo and Victor Rios, Sebastian’s parents. Children who grow up in homes where both Spanish and English are spoken are sometimes slower to develop their language skills, she said. Plus, Sebastian was developing well in other ways: when he was just […]]]>

When Sebastian Rios was very young, he barely spoke. “Don’t worry,” his pediatrician told Amparo and Victor Rios, Sebastian’s parents. Children who grow up in homes where both Spanish and English are spoken are sometimes slower to develop their language skills, she said.

Plus, Sebastian was developing well in other ways: when he was just 18 months old, for example, he could identify the magnetized letters of the alphabet on the fridge in their home in Bronxville, a short train ride away. north of New York.

But by the time Sebastian was just over 2, his skills didn’t keep up with those of other kids his age: He only spoke simple words, like “mom” and “dad”, and had interaction issues. with people, says Amparo Rios. He didn’t know how to play with other children and didn’t care to show people his toys or share them. He was making less and less eye contact.

Advertising – Continue Reading Below

The Rios feared their son had autism, but didn’t know how to get a definitive diagnosis for his lagging skills or how to get help.

According to federal estimates, one in 44 children has been diagnosed with autism spectrum disorder by age 8. It is an intellectual disability that affects people’s social and communication skills and their behavior to varying degrees. About a third of children with autism also have intellectual disabilities, according to the federal Centers for Disease Control and Prevention.

As awareness of the autism spectrum has grown, new diagnostic criteria covering milder forms of the disability have helped bring attention to the needs of children, like Sebastian, who can benefit ongoing treatment and need significant support to attend school and participate in activities. love sports.

Autism cannot be diagnosed with a blood test or a scan. Instead, professionals typically rely on in-depth interviews with parents or caregivers about a child’s development, as well as assessments of a child’s behavior in one-on-one sessions. These may require out-of-pocket payments as insurance companies impose stricter coverage standards. Parents can wait months for appointments with a developmental pediatrician or other specialists.

“There are significant shortages of providers, especially with the number of children diagnosed or suspected of having autism these days,” said Kelly Headrick, senior director of state government affairs and advocacy at base at Autism Speaks, a research and advocacy organization.

As a result, the Rios have found that getting a diagnosis and any subsequent help can be a long, winding, nerve-wracking and sometimes expensive road.

Although parents may notice developmental issues during a child’s first 18-24 months, children don’t get diagnosed with autism, on average, until they are over 4 years old, studies show. . This means missed opportunities for intervention: research shows that early treatment of autism yields better results.

Wanting to get help for Sebastian, the Rios sought help from their pediatrician when their son was 2 years old. The doctor referred them to their school district, so that Sebastian could be evaluated for special education services. But he was too young for the district to help him.

The Rios learned that children under age 3 must connect to services through the federally mandated Early Intervention Program that requires states to provide services to children with developmental delays or disabilities.

The family waited over three months for the battery of tests and appointments to be completed, and the gap between Sebastian’s development and that of other children his age continued to widen. In addition to his language and social development delays, he struggled with imaginative play and was intensely self-directed, fully focused on what he wanted to do when he wanted to.

Although the staff members of the early intervention program lacked the specialist skills necessary to provide a medical diagnosis, they recommended that Sebastian begin occupational therapy, speech therapy and applied behavior analysis, a technique widely used in which therapists work extensively with children who have autism using positive reinforcement to achieve goals related to communication, learning, motor and other skills. For example, a therapist may encourage a child to play a game the therapist has chosen before playing the game the child prefers. If the child does this, he might get praise from the therapist or get something else he enjoys, like a toy or a playground.

The early intervention program paid someone to go to the Rios’ home six hours a week for ABA therapy. But Amparo Rios said the therapist wasn’t focusing on Sebastian’s issues, such as transitioning from one activity to another without melting down, so she wanted another ABA therapist.

The Rios had health coverage through a plan administered by Trustmark, which established coverage policies in consultation with Amparo Rios’ employer, a local college. But Sebastian needed a medical diagnosis of autism from a provider the plan considered a qualified clinician before paying for ABA therapy – a diagnosis Sebastian still didn’t have at age 3. shorthand for self-stimulating behavior, often repetitive movements or sounds that help calm or comfort people with autism. In Sebastian’s case, he groaned.

Since there is no single standardized test required to diagnose the condition, providers use different tools – which some specific insurers will not accept.

The family took Sebastian to a neurologist for a checkup, but she said they weren’t sure he had autism. “We felt so rudderless,” Amparo said. “We didn’t know where to turn to diagnose him or figure out what was wrong with him.”

Six months later, in September 2020, the family found a clinical psychologist who specializes in autism spectrum disorders and is part of their network of providers. She tested Sebastian for three months, assessing his cognitive abilities and ability to complete tasks, follow instructions, and pay attention, among other things. The pandemic slowed medical care, and in May 2021 she finally diagnosed Sebastian, then 4, with Autism Spectrum Disorder Level 1, the least limiting form, and recommended that he restart ABA therapy. .

The delay cost Sebastian. His pacing behaviors worsened and he made eye contact with others less frequently. “We had very mixed feelings about the diagnosis,” Amparo said. “It was a relief that we had a diagnosis that we could rely on for medical care. But it was mixed because as parents we didn’t know what would become of him.

Two years after the Rios noticed their son’s atypical behaviors, they enrolled him in individual ABA therapy for 15 hours a week at a center near their home. It was as if the pieces were finally falling into place. Sebastian’s language skills were improving with speech therapy, but he was very independent and still not good at making eye contact. He sometimes wandered alone, a terrible risk to his safety, and couldn’t use the bathroom on his own.

Amparo’s health plan administrator, Trustmark, confirmed that ABA therapy was covered, with a co-payment of $25 per session.

It was difficult for Sebastian at first, Amparo said, as he worked with a therapist to learn how to be less rigid and less focused on just doing what he wanted to do. But he gradually improved in skills such as eye contact and using the bathroom on his own.

The relief was short-lived.

Last September, the Rios began receiving notices from the health plan administrator saying he would not pay for therapy because it was not medically necessary. Unfortunately, the therapist who provided the diagnosis had not screened Sebastian using the Autism Diagnostic Observation Program (ADOS-2), a popular test.

Sebastian’s developmental pediatrician sent a letter to the health plan explaining the need, and the ABA therapy provider sent clinical notes from Sebastian’s sessions.

It did not work. Trustmark refused to pay for ABA therapy, and in February the Rios discontinued it. Now they face more than $11,000 in bills for the sessions. Without the therapy, their son’s progress slows, Amparo said. He is more restless and has been distracted and disruptive in his kindergarten class, needing constant reminders to stay focused.

Trustmark declined to comment for this article.

“It’s really frustrating” for the parents, Amparo said, “but ultimately it’s very sad for my son.”

The Rios appealed the denial but lost. An independent reviewer found in May that ABA services were not medically necessary and questioned whether Sebastian had autism. He noted that Sebastian had not been screened using the ADOS-2 test and said he needed it.

It was the last straw. Amparo quit her job, and the family replaced her health coverage with her husband’s. They started a new assessment process for Sebastian, now 5 years old. They paid a vendor $500 to administer the ADOS-2 test, which confirmed his autism diagnosis in June. Now, three years after they started looking for help, they’re trying again to enroll Sebastian in ABA therapy using coverage from the new health plan.

“You want your child to be assessed as soon as possible to get as much help as possible,” Amparo said. “It’s a critical moment in his development, and I just feel down.”

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism on health issues. Along with policy analysis and polls, KHN is one of the three main operating programs of the KFF (Kaiser Family Foundation). KFF is an endowed non-profit organization providing information on health issues to the nation.

Read more stories like this. Sign up for Disability Scoop’s free newsletter to get the latest news on developmental disabilities delivered straight to your inbox.

]]>